Osteoporosis Drugs Market by Drug Type (Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy), Route of Administration (Injectable, Oral), Application - Global Forecast 2024-2030

Osteoporosis Drugs Market by Drug Type (Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy), Route of Administration (Injectable, Oral), Application - Global Forecast 2024-2030


The Osteoporosis Drugs Market size was estimated at USD 8.32 billion in 2023 and expected to reach USD 8.77 billion in 2024, at a CAGR 5.60% to reach USD 12.19 billion by 2030.

Global Osteoporosis Drugs MarketOsteoporosis drugs treat and prevent osteoporosis, a disorder in which bones become brittle and weak, causing them to be more susceptible to fractures. Osteoporosis is a common condition, particularly among postmenopausal women, and it can have serious consequences, including disability and chronic pain. The rising number of the elderly population, increasing awareness of osteoporosis care, and incidence of osteoporosis in postmenopausal women have significantly increased the need for osteoporosis drugs. However, the side effects of osteoporosis drugs and the time-consuming drug approval process hamper the growth of the osteoporosis drugs market. Additionally, the growing investment in drug discovery and the rising number of research activities in healthcare organizations are expected to boost osteoporosis drugs market growth in upcoming years.

Regional Insights

The Americas has a significant landscape in the osteoporosis drugs market owing to the high adoption of advanced technologies, developed healthcare infrastructure, and the high prevalence of osteoporosis. According to the National Osteoporosis Foundation, approximately 10 million Americans have osteoporosis, and another 44 million have low bone density, which increases their risk of developing the condition. Moreover, the collaborative research programs implemented by major health organizations and the development of new products in Europe, the Middle East, and Africa improve the current market environment. Additionally, the market for osteoporosis drugs in APAC is expected to grow significantly due to the increasing incidence of osteoporosis in countries such as Japan, China, and South Korea. According to the International Osteoporosis Foundation, the prevalence of osteoporosis in the Japanese female population aged 50-79 years has been estimated to be about 35% at the spine and 9.5% at the hip. The market is expected to grow in the coming years, driven by factors such as an aging population, increasing awareness about bone health, and the introduction of new and innovative osteoporosis drugs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Osteoporosis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Osteoporosis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Osteoporosis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alembic Pharmaceuticals Ltd., Alkem Laboratories Ltd., Amgen, Inc., Apotex Inc., Century Pharmaceuticals Ltd., Cipla Ltd., Cubit Healthcare, Dr. Reddy's Laboratories, Eli Lilly and Company, F.Hoffmann La Roche AG, GlaxoSmithKline PLC, Hetero Healthcare Ltd., Intas Pharmaceuticals Ltd, Macleods Pharmaceuticals Ltd., Merck & Co AG, Midas Pharma GmbH, Mylan N.V. by Viatris Inc., Natco Pharma Ltd., Novartis AG, Pfizer Inc., Polpharma, Pulse Pharmaceuticals, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Ltd, Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., and Vintage Labs Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Osteoporosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
Bisphosphonates
Calcitonin
Parathyroid Hormone Therapy
Rank Ligand Inhibitors
Selective Estrogen Inhibitors Modulator
Route of Administration
Injectable
Oral
Application
Primary Osteoporosis
Secondary Osteoporosis
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Osteoporosis Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Osteoporosis Drugs Market?
3. What are the technology trends and regulatory frameworks in the Osteoporosis Drugs Market?
4. What is the market share of the leading vendors in the Osteoporosis Drugs Market?
5. Which modes and strategic moves are suitable for entering the Osteoporosis Drugs Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Osteoporosis Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising elderly population coupled with changing lifestyle habits impacting bone health
5.1.1.2. Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
5.1.2. Restraints
5.1.2.1. Concerns over patent expiration of osteoporosis drugs
5.1.3. Opportunities
5.1.3.1. Emerging product development and research activities in healthcare organizations
5.1.3.2. Proliferation in the research funding from various organizations
5.1.4. Challenges
5.1.4.1. Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Osteoporosis Drugs Market, by Drug Type
6.1. Introduction
6.2. Bisphosphonates
6.3. Calcitonin
6.4. Parathyroid Hormone Therapy
6.5. Rank Ligand Inhibitors
6.6. Selective Estrogen Inhibitors Modulator
7. Osteoporosis Drugs Market, by Route of Administration
7.1. Introduction
7.2. Injectable
7.3. Oral
8. Osteoporosis Drugs Market, by Application
8.1. Introduction
8.2. Primary Osteoporosis
8.3. Secondary Osteoporosis
9. Americas Osteoporosis Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Osteoporosis Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Osteoporosis Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Merger & Acquisition
12.3.1.1. Amgen to Acquire Horizon for USD 27.8 Billion, Expanding Rare Disease Pipeline.
12.3.1.2. Tymlos maker Radius Health sells itself to investment firms for USD 890 Million..
12.3.2. Agreement, Collaboration, & Partnership
12.3.2.1. WHO and ESCEO announce collaborative agreement to benefit global osteoporosis and fracture prevention.
12.3.2.2. Akums Drugs ties up with Microcore Research to manufacture NESM supplements.
12.3.2.3. Lupin signs agreement with I’rom for clinical trials and marketing of post-menopause drug in Japan.
12.3.3. New Product Launch & Enhancement
12.3.3.1. Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment
12.3.4. Investment & Funding
12.3.4.1. New funding for osteoporosis research announced
12.3.5. Award, Recognition, & Expansion
12.3.5.1. FDA Clears Tymlos for Osteoporosis in Men
12.3.5.2. EVENITY (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
12.3.5.3. Pharmanovia expands its footprint in China with the acquisition of Rocaltrol from Roche
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. Alembic Pharmaceuticals Ltd.
13.1.3. Alkem Laboratories Ltd.
13.1.4. Amgen, Inc.
13.1.5. Apotex Inc.
13.1.6. Century Pharmaceuticals Ltd.
13.1.7. Cipla Ltd.
13.1.8. Cubit Healthcare
13.1.9. Dr. Reddy's Laboratories
13.1.10. Eli Lilly and Company
13.1.11. F.Hoffmann La Roche AG
13.1.12. GlaxoSmithKline PLC
13.1.13. Hetero Healthcare Ltd.
13.1.14. Intas Pharmaceuticals Ltd
13.1.15. Macleods Pharmaceuticals Ltd.
13.1.16. Merck & Co AG
13.1.17. Midas Pharma GmbH
13.1.18. Mylan N.V. by Viatris Inc.
13.1.19. Natco Pharma Ltd.
13.1.20. Novartis AG
13.1.21. Pfizer Inc.
13.1.22. Polpharma
13.1.23. Pulse Pharmaceuticals
13.1.24. Steris Healthcare Pvt. Ltd.
13.1.25. Sun Pharmaceutical Industries Ltd
13.1.26. Taj Pharmaceuticals Ltd.
13.1.27. Teva Pharmaceutical Industries Ltd.
13.1.28. Vintage Labs Pvt. Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. OSTEOPOROSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. OSTEOPOROSIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. OSTEOPOROSIS DRUGS MARKET DYNAMICS
FIGURE 7. OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings